STALEY CAPITAL ADVISERS’s MoonLake Immunotherapeutics MLTX Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-580,000	Closed	-$6.35M	–	177
2022 Q1	$6.35M	Hold	580,000	–	–	0.32%	51
2021 Q4	$5.74M	Hold	580,000	–	–	0.27%	57
2021 Q3	$5.71M	Buy	580,000 +80,000	+16%	+$798K	0.31%	53
2021 Q2	$5.17M	Buy	500,000 +200,000	+67%	+$2.03M	0.27%	56
2021 Q1	$3.06M	Buy	300,000 +253,879	+550%	+$2.8M	0.17%	68
2020 Q4	$524K	Buy	+46,121	New	+$490K	0.03%	118

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

STALEY CAPITAL ADVISERS's MLTX Position: Q2 2022 in Review

STALEY CAPITAL ADVISERS sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 580,000 shares — an estimated $6.35M sold.

STALEY CAPITAL ADVISERS first reported a position in MLTX in Q4 2020 and held it in 6 quarters. The position peaked at $6.35M in Q1 2022. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

STALEY CAPITAL ADVISERS reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
STALEY CAPITAL ADVISERS sold 580,000 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $6.35M.
STALEY CAPITAL ADVISERS first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 6 quarters.
STALEY CAPITAL ADVISERS's MoonLake Immunotherapeutics position peaked at $6.35M in Q1 2022.
23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q2 2022, filed 5 Aug 2022.